

Table S8. Defined daily dose of NOACs of the users of CYP3A4/P-gp inhibitors and inducers.

	Defined daily dose of NOACs							
	Dabigatran		Rivaroxaban		Apixaban		Edoxaban	
	Cases	Controls	Cases	Controls	Cases	Controls	Cases	Controls
CYP3A4/P-gp inhibitors, mean ± SD	57.8 ± 17.4	60.4 ± 17.5	54.6 ± 16.8	55.3 ± 16.6	59.0 ± 27.9	58.0 ± 23.4	36.0 ± 24.5	42.9 ± 24.1
CYP3A4/P-gp inducers, mean ± SD	55.2 ± 19.1	64.3 ± 16.5	53.3 ± 16.8	57.4 ± 17.0	54.7 ± 29.4	70.1 ± 23.6	47.0 ± 21.7	64.5 ± 23.5

CYP3A4: cytochrome P450 3A4; NOACs: non-vitamin-K antagonist oral anticoagulants; SD: standard deviation